期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 121, 期 6, 页码 878-883出版社
AMER SOC CLINICAL PATHOLOGY
DOI: 10.1309/A7M2XTMJQK0KPQER
关键词
KIT; CD117; immunohistochemistry; mutation; renal cell carcinoma; chromophobe renal cell carcinoma; oncocytoma; angiomyolipoma
类别
KIT expression has not been studied substantially in renal tumors. We analyzed the immunohistochemical expression for KIT in 256 conventional renal cell carcinomas (RCCs), 29 chromophobe RCCs, 25 papillary RCCs, 6 collecting duct RCCs, 6 unclassified RCCs, 7 renal oncocytomas, 20 urothelial carcinomas, 7 nephroblastomas, and 23 angiomyolipomas. We found that 24 chromophobe RCCs (83%) and 5 renal oncocytomas (71%) revealed membranous immunoreactivity for KIT, while none of the RCCs of other types expressed KIT immunohistochemically Sporadic cases of urothelial carcinoma and nephroblastoma were,focally positive for KIT All angiomyolipomas were negative. Genomic DNA extracted from the chromophobe RCCs and renal oncocytomas was submitted for polymerase chain reaction and direct sequencing of the juxtamembrane (exons 9 and 11) and tyrosine kinase (exons 13 and 17) domains. No mutation was found. Our results demonstrate that KIT could be a useful immunophenotypic marker for chromophobe RCC and renal oncocytoma; therefore, it has value for the precise classification of renal cortical epithelial tumors. However, the therapeutic relevance of KIT overexpression in these tumors is uncertain owing to the lack of mutations that would lead to constitutive activation of the protein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据